Instenon

combination containing hydroxyethyltheophylline, hexobendine & vanillic acid diethylamide

Also Known As:

3,4,5-trimethoxybenzoic acid 1,2-ethanediylbis(methylimino)-3,1-propanediyl) ester mixt. with N,N-diethyl-4-hydroxy-3-methoxybenzamide & 3,7- dihydro-7-(2-hydroxyethyl)-1,3-dimethyl-1H-purine- 2,6-dione

Networked: 13 relevant articles (3 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Aznabaev, M T: 1 article (11/2003)
2.	Khalikov, V A: 1 article (11/2003)
3.	Zagidullina, A Sh: 1 article (11/2003)
4.	Ovchinnikova, A A: 1 article (01/2002)
5.	Rumiantseva, M V: 1 article (01/2002)
6.	Suvorinova, N Iu: 1 article (01/2002)
7.	Zavadenko, N N: 1 article (01/2002)
8.	Eryshev, O F: 1 article (01/2000)
9.	Kudriavtsev, A A: 1 article (01/2000)
10.	Tskhovelidze, G G: 1 article (01/2000)

Related Diseases

1.	Cerebrovascular Disorders (Cerebrovascular Occlusion) 10/08/1969 - "[Treatment of acute cerebrovascular insufficiency using Instenon]." 01/01/1997 - "Application of Instenon in form of ampules was more effective in patients with disorders of consciousness while usage of drug in the form of dragee was more effective in patients with cerebrovascular disorders in vertebro-basilar system. " 01/26/1968 - "[Studies of the administration of ustimon and instenon in cerebrovascular diseases]." 01/27/1967 - "[Indications for Ustimon and Instenon therapy in cerebrovascular diseases]."
2.	Craniocerebral Trauma (Head Injury) 08/16/1973 - "[Treatment of craniocerebral injuries using Instenon]." 11/01/2003 - "[Use of instenon in complex treatment of patients with optic nerve atrophy caused by craniocerebral trauma]." 11/01/2003 - "Our study revealed that instenon, when used within a complex treatment of a partial optic nerve atrophy caused by craniocerebral trauma, improved the visual acuity in 85.7% of patients and it expanded the total visual field in 76.2% of patients, whereas the routine therapy ensured the related improvements in 58.9% and 61.5% of patients, respectively. " 11/01/2003 - "Instenon, a combined nootropic agent, was used on the step-type basis within a complex treatment of optic nerve atrophy caused by craniocerebral trauma. "
3.	Atrophy 11/01/2003 - "[Use of instenon in complex treatment of patients with optic nerve atrophy caused by craniocerebral trauma]." 11/01/2003 - "Our study revealed that instenon, when used within a complex treatment of a partial optic nerve atrophy caused by craniocerebral trauma, improved the visual acuity in 85.7% of patients and it expanded the total visual field in 76.2% of patients, whereas the routine therapy ensured the related improvements in 58.9% and 61.5% of patients, respectively. " 11/01/2003 - "Instenon, a combined nootropic agent, was used on the step-type basis within a complex treatment of optic nerve atrophy caused by craniocerebral trauma. "
4.	Consciousness Disorders 01/01/1996 - "[The use of Instenon to correct a postanesthesia consciousness disorder in surgical patients]." 01/01/1997 - "Application of Instenon in form of ampules was more effective in patients with disorders of consciousness while usage of drug in the form of dragee was more effective in patients with cerebrovascular disorders in vertebro-basilar system. "
5.	Alcoholism (Alcohol Abuse) 01/01/2000 - "[Effectiveness of instenon ++ in the period of the development of remission in alcoholism]."

Related Drugs and Biologics

1.	Hexobendine
2.	Actovegin
3.	Nootropic Agents (Nootropics)

Related Therapies and Procedures

1.	Therapeutics
2.	Intravenous Injections